OpenLB
Open Library of Bioscience
Advanced Search
Epilepsy & behavior : E&B
10, 2022;135 108900.

Long-term analysis of the effects of COVID-19 in people with epilepsy: Results from a multicenter on-line survey across the pandemic waves.

Chiara Parodi, Ilaria Viganò, Emerenziana Ottaviano, Valentina Massa, Elisa Borghi, Simone Beretta, Jacopo C Di Francesco, Valeria Badioni, Aglaia Vignoli, COV-EPI Study Group
Author Information
  1. Chiara Parodi: Department of Health Sciences, Università degli Studi di Milano, Milan, Italy.
  2. Ilaria Viganò: Department of Health Sciences, Università degli Studi di Milano, Milan, Italy.
  3. Emerenziana Ottaviano: Department of Health Sciences, Università degli Studi di Milano, Milan, Italy.
  4. Valentina Massa: Department of Health Sciences, Università degli Studi di Milano, Milan, Italy; "Aldo Ravelli" Center for Neurotechnology and Experimental Brain Therapeutics, Università degli Studi di Milano, Milan, Italy.
  5. Elisa Borghi: Department of Health Sciences, Università degli Studi di Milano, Milan, Italy.
  6. Simone Beretta: Epilepsy Center, ASST San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy.
  7. Jacopo C Di Francesco: Epilepsy Center, ASST San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy.
  8. Valeria Badioni: Neurology Unit, ASST Lodi, Lodi, Italy.
  9. Aglaia Vignoli: Department of Health Sciences, Università degli Studi di Milano, Milan, Italy; Neuropsychiatry of Childhood and Adolescence, ASST GOM Niguarda, Ospedale Niguarda Ca' Granda, Milan, Italy. Electronic address: aglaia.vignoli@unimi.it.
PMID: 36115083 DOI: 10.1016/j.yebeh.2022.108900

Abstract

PURPOSE: The worldwide pandemic caused by SARS-CoV-2 virus posed many challenges to the scientific and medical communities, including the protection and management of fragile populations. People with epilepsy (PWE) are a heterogenous group of subjects, with different treatment regimens and severity of symptoms. During the National lockdown, in Italy many patients with chronic conditions lost their regular follow-up program. The aim of this study was to investigate the impact of COVID-19 on their health status, from the start of the pandemic (March 2020) to July 2021 and one year later.
METHODS: We proposed an online questionnaire to subjects followed up at different epilepsy centers located in Milano, Monza & Lodi, three of Lombardy, Northern Italy, the most affected areas by the pandemic. Survey evaluated age, sex, characteristics of patients, type of epilepsy and therapies, COVID-19 diagnosis, vaccines, sleep quality, and anxiety status.
RESULTS: Among 178 analyzed surveys, 37 individuals reported symptoms of COVID-19 in closed contacts, including 9 with molecular diagnosis and 16 PWE performing the nasopharyngeal swab with 3 positive cases. One year later, 35 individuals reported at least one symptom overlapping with those typical of COVID-19, 8 received COVID-19 diagnosis, among which 6 were positive for SARS-CoV-2 infection. According to the sleep quality scale assessment, most PWE (52.3%) had poor sleep quality. Assessing anxiety status, 32 (38.1%) had a pathological score.
CONCLUSION: In this multicenter study, we observed that PWE do not appear to be at a higher risk of severe COVID-19. It will be fundamental monitoring this group to assess possible differences in long-COVID-19 and/or neuro-COVID-19 prevalence. On the other hand, our survey confirmed the impact of the pandemic on anxiety and quality of sleep in PWE. Thus, it is important to promptly recognize and treat psychological distress in PWE, because it could be a risk factor in seizure aggravation and quality-of-life deterioration. Telemedicine appears to be a useful tool to support patients with chronic diseases, such as epilepsy.

Keywords

Antiseizure medications COVID-19 Epilepsy SARS-CoV-2

References

JAMA Intern Med. 2021 Feb 1;181(2):269-271 [PMID: 33104158]
Epilepsy Behav. 2021 Dec;125:108410 [PMID: 34781062]
Seizure. 2021 May;88:102-108 [PMID: 33839561]
Epilepsy Behav. 2020 Dec;113:107527 [PMID: 33242768]
Epilepsy Behav. 2021 Sep 29;124:108340 [PMID: 34600283]
Seizure. 2021 Nov;92:2-9 [PMID: 34391030]
Acta Neurol Scand. 2021 Jun;143(6):624-628 [PMID: 33590880]
Epilepsia. 2020 Sep;61(9):1840-1853 [PMID: 32944929]
Epilepsy Behav. 2020 Nov;112:107298 [PMID: 32801068]
Epilepsy Behav. 2020 Nov;112:107396 [PMID: 32911299]
Int J Infect Dis. 2020 Feb;91:264-266 [PMID: 31953166]
Seizure. 2020 Jul;79:49-52 [PMID: 32416567]
Front Neurol. 2020 Jul 03;11:737 [PMID: 32719655]
Neurology. 2020 Sep 8;95(10):e1417-e1425 [PMID: 32554773]
ACS Pharmacol Transl Sci. 2020 Nov 11;3(6):1361-1370 [PMID: 34778724]
Acta Neurol Scand. 2020 Dec;142(6):545-554 [PMID: 32799337]
J Clin Neurosci. 2020 Jul;77:8-12 [PMID: 32409215]
Epilepsy Behav. 2021 Mar;116:107785 [PMID: 33515934]
Eur J Neurol. 2021 Jan;28(1):7-14 [PMID: 33058321]
JAMA Neurol. 2020 Aug 1;77(8):927-928 [PMID: 32329796]
Psychiatry Res. 1989 May;28(2):193-213 [PMID: 2748771]
Acta Neurol Scand. 2021 Feb;143(2):206-209 [PMID: 32990951]
JAMA. 2020 Apr 28;323(16):1574-1581 [PMID: 32250385]
N Engl J Med. 2020 Feb 20;382(8):727-733 [PMID: 31978945]
Epilepsy Behav. 2021 Jul;120:107996 [PMID: 33957438]
Front Neurol. 2020 Jun 26;11:722 [PMID: 32714276]
Lancet Planet Health. 2021 Oct;5(10):e671-e680 [PMID: 34627471]
Epilepsia. 2020 Jun;61(6):1166-1173 [PMID: 32353184]
Eur J Pharmacol. 2021 May 5;898:173988 [PMID: 33667455]
Epileptic Disord. 2021 Apr 1;23(2):257-267 [PMID: 33772512]
J Med Virol. 2021 Jan;93(1):250-256 [PMID: 32592501]
Neurosciences (Riyadh). 2020 Jul;25(3):222-225 [PMID: 32683406]
JAMA Netw Open. 2021 Nov 1;4(11):e2134147 [PMID: 34762110]
Seizure. 2021 Mar;86:60-67 [PMID: 33550135]
Epilepsy Behav. 2020 Jul;108:107122 [PMID: 32361677]
Neurology. 2020 Aug 25;95(8):e1060-e1070 [PMID: 32482845]
Epilepsia. 2021 Oct;62(10):2322-2332 [PMID: 34428314]
Epilepsy Behav. 2020 Nov;112:107323 [PMID: 32712565]
Digit Health. 2021 Apr 19;7:20552076211009396 [PMID: 33959378]
Isr Med Assoc J. 2020 Nov;11(22):665-672 [PMID: 33249784]
J Infect. 2020 Jun;80(6):607-613 [PMID: 32283152]
Neurocrit Care. 2021 Jun;34(3):1062-1071 [PMID: 32661794]
Epilepsy Behav. 2021 Feb;115:107602 [PMID: 33279440]
Epileptic Disord. 2020 Aug 1;22(4):439-442 [PMID: 32759092]
Epilepsia. 2020 Aug;61(8):e95-e100 [PMID: 32697361]
Int J Environ Res Public Health. 2019 Feb 21;16(4): [PMID: 30795623]
Front Neurol. 2020 Aug 19;11:870 [PMID: 32973656]
Epilepsy Behav. 2021 Mar;116:107740 [PMID: 33545652]
Nature. 2020 Jul;583(7816):459-468 [PMID: 32353859]
Epilepsia. 2018 Dec;59(12):2179-2193 [PMID: 30426482]

MeSH Term

COVID-19
COVID-19 Testing
Communicable Disease Control
Epilepsy
Humans
Pandemics
SARS-CoV-2
Surveys and Questionnaires
Post-Acute COVID-19 Syndrome
Journal Article Multicenter Study

Word Cloud

Similar Articles

Cited By